该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月3日收盘，大博医疗(002901)报收于49.75元，上涨1.12%，换手率 0.64%，成交量1.85万手，成交额9164.35万元。 2月3日的资金流向数据方面，主力资金净流出278.38万元，占总成交额3.04%，游资资金净流入158.74 万元，占总成交额1.73%，散户资金净流入119.64万元，占总成交额1.31%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-03 | 49.75 | 1.12% | -278.38万 | -3.04% | 158.74万 | 1.73% | 119.64万 | 1.31% | | 2026-02-02 | 49.20 | -3.77% | + -51.34万 | -0.36% | 317.70万 | 2.22% | -266.36万 | -1.86% | | 202 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-28 | 51.22 -1.31% | | -423.06万 | -2.10% | 568.46万 | 2.82% | -145.40万 | -0.72% | | 2026-01-27 | 51.90 7.45% | | 1299.83万 | 3.51% | -987.92万 | -2.67% | -311.91万 | -0.84% | | 2026-01-26 | 48.30 -3.69% | | -181.70万 | -1.25% | 1052.12万 | 7.26% | -870.43万 | -6.00% | | 2026-01-23 | 50.15 | 1.48% | -169.77万 | -1.67% | -481.25万 | -4.73% | 651.02万 | 6.40% | | 2026-01-22 49.42 -1.06% | | | -19 ...

证券之星消息，截至2026年1月27日收盘，大博医疗(002901)报收于51.9元，上涨7.45%，换手率 2.51%，成交量7.24万手，成交额3.71亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 1月27日的资金流向数据方面，主力资金净流入1299.83万元，占总成交额3.51%，游资资金净流出 987.92万元，占总成交额2.67%，散户资金净流出311.91万元，占总成交额0.84%。 该股最近90天内共有1家机构给出评级，买入评级1家。 近5日资金流 ...

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a substantial growth of 77.03% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up by 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a year-on-year increase of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up by 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 23, 2026, Dabo Medical's stock closed at 50.15 yuan, with an increase of 1.48% [1]. - The trading volume was 20,400 hands, with a total transaction amount of 102 million yuan [1]. - The net outflow of main funds was 1.6977 million yuan, accounting for 1.67% of the total transaction amount, while retail investors saw a net inflow of 6.51 million yuan, representing 6.4% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Dabo Medical [3].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][3]. Group 1: Stock Performance - As of January 22, 2026, Dabo Medical's stock closed at 49.42 yuan, down 1.06% with a turnover rate of 0.58% and a trading volume of 16,800 lots, amounting to a transaction value of 83.36 million yuan [1]. - The net outflow of main funds on January 22 was 1.92 million yuan, accounting for 2.31% of the total transaction value, while retail investors saw a net inflow of 1.26 million yuan, representing 1.51% of the total [1]. Group 2: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.461 billion yuan, significantly higher than the industry average of 11.31 billion yuan, ranking 12th out of 127 companies in the medical device sector [2]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, a year-on-year increase of 77.03%, with a gross margin of 71.23%, which is well above the industry average of 50.94% [2]. - The company's return on equity (ROE) stands at 12.83%, placing it 7th in the industry, while its price-to-earnings ratio (P/E) is 36.14, significantly lower than the industry average of 97.34 [2].

Core Viewpoint - Dabo Medical (002901) reported a decline in stock price and mixed capital flow data, indicating potential investor caution despite strong financial performance in recent quarters [1][2]. Financial Performance - For the first three quarters of 2025, Dabo Medical achieved a main operating revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The non-recurring net profit was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company reported a main operating revenue of 666 million yuan, a 17.82% increase compared to the same quarter last year [2]. - The net profit for Q3 2025 was 180 million yuan, showing a year-on-year increase of 77.49% [2]. - The non-recurring net profit for Q3 2025 was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with an investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Capital Flow - On January 7, 2026, Dabo Medical's stock closed at 49.48 yuan, down 1.61%, with a turnover rate of 0.68% and a trading volume of 19,500 hands, resulting in a transaction amount of 97.09 million yuan [1]. - The capital flow data for January 7 indicates a net outflow of 10.69 million yuan from main funds, accounting for 11.02% of the total transaction amount [1]. - Retail investors contributed a net inflow of 8.29 million yuan, representing 8.54% of the total transaction amount [1].

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a 77.03% increase year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a 17.82% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 5, 2026, Dabo Medical's stock closed at 49.63 yuan, up 4.77%, with a turnover rate of 1.07% and a trading volume of 30,900 hands, amounting to a transaction value of 152 million yuan [1]. - On January 5, the net outflow of main funds was 15.42 million yuan, accounting for 10.17% of the total transaction value, while retail investors saw a net inflow of 26.27 million yuan, representing 17.32% of the total transaction value [1].

Core Viewpoint - The company operates in the medical device distribution industry, focusing on high-value medical consumables and IVD diagnostic products, with a strategy to enhance its market share through differentiated operational capabilities and digital applications [2] Group 1: Industry Overview - The medical device distribution industry is characterized by a relatively fragmented market share for the company's core products, which include vascular intervention and surgical products, as well as IVD diagnostic products [2] - The company aims to leverage national sales networks, specialized operational capabilities, and digital development applications to differentiate itself from traditional medical device distributors and pharmaceutical wholesalers [2] Group 2: Business Strategy - The company plans to capitalize on existing mature market shares in the medical device distribution sector, particularly in the context of centralized procurement policies [2] - The company will actively pursue the commercialization of innovative medical devices, supported by encouraging policies for innovation [2] - Focus on centralized management supply for key hospitals during the full implementation phase of the medical reform DRG policy represents a new market segment for the company [2] Group 3: Competitive Positioning - The company's operational capabilities and digital applications are expected to enhance its position in both existing and emerging markets within the medical device distribution field [2] - The company aims for steady growth to improve its industry standing by learning from competitors and maintaining a robust competitive edge [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 29, 2025, showing a slight decline in stock price and notable changes in capital flow [1][2]. Group 2 - Dabo Medical reported a main revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, up 77.03% year-on-year, while the net profit after deducting non-recurring items was 346 million yuan, an increase of 63.99% [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 666 million yuan, reflecting a year-on-year growth of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, up 77.49% year-on-year, and the net profit after deducting non-recurring items was 123 million yuan, increasing by 38.44% [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan, while the gross profit margin is 71.23% [2]. - Dabo Medical specializes in the production, research, and sales of high-value medical consumables [2]. Group 3 - Over the last 90 days, one institution has given a buy rating for Dabo Medical [3]. - The capital flow data indicates a net outflow of 9.4984 million yuan from main funds, accounting for 12.08% of the total transaction amount, while retail investors saw a net inflow of 8.1568 million yuan, representing 10.37% of the total transaction amount [1].

Core Viewpoint - The stock of Dabo Medical (002901) shows a slight increase in price and mixed capital flow, indicating varying investor sentiment and potential opportunities for analysis [1][2]. Group 1: Stock Performance - As of December 23, 2025, Dabo Medical's stock closed at 49.61 yuan, with a minor increase of 0.1% and a turnover rate of 0.6% [1]. - The trading volume on December 23 was 17,400 hands, with a total transaction value of 86.5954 million yuan [1]. Group 2: Capital Flow Analysis - On December 23, the net inflow of main funds was 2.6422 million yuan, accounting for 3.05% of the total transaction value, while retail investors saw a net inflow of 3.3368 million yuan, representing 3.85% [1][2]. - In contrast, speculative funds experienced a net outflow of 5.979 million yuan, which is 6.9% of the total transaction value [1][2]. Group 3: Financial Metrics and Industry Ranking - Dabo Medical's total market capitalization is 20.54 billion yuan, significantly higher than the industry average of 10.786 billion yuan, ranking 10th out of 125 in the medical device sector [3]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 77.03%, with a gross margin of 71.23% [3]. - The company's return on equity (ROE) stands at 12.83%, which is substantially higher than the industry average of 0.23%, ranking 7th out of 125 [3].